Severe, disabling neurologic toxicity following cisplatin retreatment.
OBJECTIVE
To describe a severe neurotoxic reaction following the second cycle of cisplatin-based chemotherapy.


METHODS
A patient with unresectable non-small-cell lung cancer was treated with combined chemotherapy and radiotherapy. Thirty-six hours after the second course of chemotherapy, the patient developed severe mental status changes consisting of aphasia, confusion, and agitation. Complete neurologic workup was most consistent with an acute vascular event.


CONCLUSIONS
Reports of acute cisplatin-induced neurologic toxicity involving the central nervous system are rare. Potential risk factors are described. Mechanisms of chemotherapy-induced vascular damage are discussed.


CONCLUSIONS
Total dosage and administration schedule of cisplatin are associated with an increased incidence of neuropathy. However, factors predicting the development of early, acute neurotoxicity are limited by the rarity of these events. It is probable that acute neurotoxic reactions in cancer patients are caused by an unknown complex of interactions involving drugs, tumor, and host factors.
Higa
G M
GM
School of Pharmacy, West Virginia University, Morgantown 26506, USA.
Wise
T C
TC
Crowell
E B
EB
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced; D003131:Combined Modality Therapy; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy
D005047:Etoposide; D002945:Cisplatin